|
KMID : 1011920200210010007
|
|
International Journal of Arrhythmia
2020 Volume.21 No. 1 p.7 ~ p.7
|
|
|
Effect of carvedilol on premature ventricular complexes originating from the ventricular outflow tract
|
|
Hwang Jong-Min
Lee Kyoung-Min
Han Seong-Wook
Bae Han-Joon
Choi Sang-Woong
Lee Cheol-Hyun
Kim In-Cheol
Cho Yun-Kyeong
Park Hyoung-Seob
Yoon Hyuck-Jun
Kim Hyung-Seop
Nam Chang-Wook
Hur Seung-Ho
|
|
|
Abstract
|
|
|
Background: Carvedilol is one of the most effective beta-blockers in reducing ventricular tachyarrhythmias and mortality in patients with heart failure. One of the possible antiarrhythmic mechanisms of carvedilol is the suppression of store overload-induced Ca2+ release, especially for the triggered activity.
Objectives: Premature ventricular complex (PVC) originating from the ventricular outflow tract (OT) is the most common form of idiopathic PVC, and its main mechanism is related to triggered activity. We evaluate the efficacy of carvedilol to suppress the OT PVC.
Methods: The electronic medical records at our hospital were screened to identify OT PVC patients treated with carvedilol. Clinical, electrocardiographic, and Holter monitoring studies were reviewed.
Results: A total of 25 patients who underwent Holter monitoring before and after carvedilol administration were found and enrolled. The mean age of the patients was 54.9?±?13.9 years, and the mean dose of carvedilol was 18.2?±?10.2 mg (sustained release formulation, 8/16/32 mg). The 24-h burden of PVC in 18 (72%) of 25 patients was significantly reduced from 12.2?±?9.7% to 4.4?±?6.7% (P?=?0.006). In seven patients, the burden of PVC was changed from 7.1?±?6.1% to 9.8?±?8.4% (P?=?0.061). There was no difference in age, carvedilol dose, duration of treatment, ventricular function, and left atrial size between responding and non-responding groups.
Conclusion: In this retrospective pilot study, treatment with carvedilol showed PVC suppression in 72% of patients. Now, we are conducting a prospective, randomized, multicenter study to evaluate the effect of carvedilol on OT PVC (Clinical trial registration: FOREVER trial, Clinical-Trials.gov: NCT03587558).
|
|
|
KEYWORD
|
|
|
Carvedilol, Premature ventricular complex, Ryanodine receptor calcium release, Triggered activity
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|
|